Scarica l'app Stockscreener
150.03
0.73%
1.08
Pre-mercato:
149.50
-0.53
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V. - MarketBeat
Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals - Yahoo Finance
Gilead Sciences, Inc. $GILD Holdings Cut by Rafferty Asset Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by DNB Asset Management AS - MarketBeat
Argent Trust Co Buys 21,785 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange By Investing.com - Investing.com South Africa
P/E Ratio Insights for Gilead Sciences - Benzinga
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector? - Barchart.com
Handelsbanken Fonder AB Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Q3 EPS Estimates for Gilead Sciences Cut by Zacks Research - MarketBeat
MAI Capital Management Purchases 13,649 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Erste Asset Management GmbH Sells 30,299 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Clifford Swan Investment Counsel LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Grants County College of Morris Foundation $150,000 Towards New Center for Health Professions Building - TAPinto
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race - GlobeNewswire Inc.
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $161.00 - MarketBeat
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data - BioSpace
Mitsubishi UFJ Asset Management Co. Ltd. Has $287.48 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Q1 EPS Forecast Lifted by Zacks Research - MarketBeat
Fox Run Management L.L.C. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace
Gilead Sciences (GILD) HIV Pill Shows Promising Results in Phase 3 Trials - GuruFocus
Gilead reports positive phase 3 data for HIV treatment combo - Investing.com
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials - Intellectia AI
Gilead (GILD) Introduces Promising HIV Treatment in Phase 3 Tria - GuruFocus
Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters
Gilead's New HIV Treatment Shows Promise in Phase 3 Trials - Intellectia AI
Gilead HIV drug combination maintains viral suppression in phase 3 trials - StreetInsider
Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma
Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating - marketscreener.com
UBS reiterates Buy on Gilead stock after Aclx acquisition - Investing.com
UBS reiterates Buy on Gilead stock after Aclx acquisition By Investing.com - Investing.com UK
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… - marketscreener.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead to Acquire Arcellx for Up to $7.8 Billion, Doubling Down on Next-Generation CAR-T Therapy - NAI500
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Arcellx Stock Explodes 77% After Gilead’s $7.8 Billion Takeover Announcement. Here’s What Investors Should Know - TIKR.com
Gilead Sciences acquires biotech company Arcellx for $7.8 billion - AKM.RU
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - TradingView
Gilead’s Arcellx Deal Deepens Oncology Focus And Raises Valuation Questions - simplywall.st
Gilead to acquire Rockville-area cancer drug developer Arcellx in $8B deal - Technical.ly
Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next - TechStock²
Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says - marketscreener.com
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld MedTech
Truist reiterates Gilead Sciences stock rating on Arcellx deal - Investing.com UK
GILD touches the ceiling: Gilead Sciences pulls back after tagging upper channel resistance - FXStreet
Gilead's $7.8 Billion Bet on Arcellx: A New Era for Multiple Myeloma Therapy Begins - Investing News Network
Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx - European Pharmaceutical Review
Gilead Sciences, Inc. $GILD Shares Bought by Nkcfo LLC - MarketBeat
Pharma Pulse: Eli Lilly’s Multi-Dose Breakthrough and Gilead’s $7.8 Billion Oncology Bet - Pharmaceutical Commerce
Gilead acquires US biotech company for nearly USD 8bn - medwatch.com
AXQ Capital LP Buys Shares of 13,757 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Price Target Increased by 11.73% to 159.01 - Nasdaq
UBS downgrades Arcellx stock rating to neutral on Gilead acquisition - Investing.com
Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx - The Daily Upside
Gilead to buy Arcellx in nearly $8B deal - statnews.com
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
With $7.8B takeout, Gilead sees Arcellx’s cell therapy as competitive with J&J’s - biocentury.com
Gilead brings Arcellx fully under the fold for $7.8B - BioWorld MedTech
Gilead’s Bictegravir/Lenacapavir Noninferiority Data Will Support Switching From Biktarvy - Citeline News & Insights
Why Gilead plans to buy a Bay Area company for $7.8 billionSan Francisco Business Times - The Business Journals
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - AOL.com
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J - Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences - The Joplin Globe
0.83%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):